CX Institutional Grows Position in Eli Lilly and Company $LLY

Key Points

• CX Institutional increased its stake in Eli Lilly and Company (NYSE: LLY) by 6.4% during the second quarter, acquiring an additional 1,744 shares, bringing its total holdings to 28,967 shares valued at approximately $22.58 million.
• Several institutional investors have significantly increased their positions in Eli Lilly, including PNC Financial Services, which raised its stake by 97.5%, and GAMMA Investing, which increased its position by an astounding 103,831.6%.
• Eli Lilly reported strong earnings with an EPS of $6.31 for the last quarter, exceeding estimates and achieving a 37.6% revenue increase versus the prior year.

CX Institutional boosted its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 6.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 28,967 shares of the company's stock after buying an additional 1,744 shares during the period. Eli Lilly and Company makes up approximately 0.8% of CX Institutional's investment portfolio, making the stock its 29th largest holding. CX Institutional's holdings in Eli Lilly and Company were worth $22,580,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of LLY. PNC Financial Services Group Inc. lifted its holdings in Eli Lilly and Company by 97.5% in the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock valued at $83,669,349,000 after acquiring an additional 50,002,551 shares during the period. GAMMA Investing LLC lifted its holdings in Eli Lilly and Company by 103,831.6% in the first quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock valued at $12,278,292,000 after acquiring an additional 14,852,076 shares during the period. Nuveen LLC acquired a new position in Eli Lilly and Company in the first quarter valued at approximately $4,613,912,000. Vanguard Group Inc. lifted its holdings in Eli Lilly and Company by 6.7% in the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock valued at $65,432,218,000 after acquiring an additional 4,975,395 shares during the period. Finally, Cohen Investment Advisors LLC lifted its holdings in Eli Lilly and Company by 7,975.5% in the first quarter. Cohen Investment Advisors LLC now owns 783,651 shares of the company's stock valued at $647,225,000 after acquiring an additional 773,947 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have issued reports on LLY. HSBC raised Eli Lilly and Company from a "reduce" rating to a "hold" rating and boosted their price target for the company from $675.00 to $700.00 in a report on Wednesday, August 27th. Guggenheim reduced their target price on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating for the company in a research note on Wednesday, August 13th. Leerink Partnrs downgraded Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 7th. Erste Group Bank downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. Finally, Daiwa America downgraded Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $939.61.

Eli Lilly and Company Trading Up 0.4%

NYSE:LLY traded up $3.33 during trading hours on Monday, hitting $755.32. The company had a trading volume of 2,524,436 shares, compared to its average volume of 4,097,673. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The company has a 50-day moving average of $738.37 and a 200 day moving average of $769.80. The company has a market cap of $714.88 billion, a P/E ratio of 49.37, a P/E/G ratio of 1.05 and a beta of 0.47. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $939.30.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm's quarterly revenue was up 37.6% on a year-over-year basis. During the same period in the prior year, the business earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Insider Buying and Selling

In other Eli Lilly and Company news, Director Jamere Jackson purchased 200 shares of the stock in a transaction dated Friday, August 8th. The stock was acquired at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the acquisition, the director owned 9,402 shares in the company, valued at $6,013,143.12. This trade represents a 2.17% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gabrielle Sulzberger purchased 117 shares of the stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the acquisition, the director owned 2,703 shares in the company, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their position. The disclosure for this purchase can be found here. Insiders bought 4,514 shares of company stock worth $2,894,841 over the last quarter. Corporate insiders own 0.14% of the company's stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.